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Inhibition of HIV-1 progeny virion release by cell-surface CD4 is
relieved by expression of the viral Nef protein
Ted M. Ross*, Alp E. Oran* and Bryan R. Cullen†
Background: The human immunodeficiency virus type 1 (HIV-1) Nef protein is
required for efficient virus replication in vivo and displays a number of distinct
and apparently unrelated biological activities in vitro. Of these, one of the most
readily demonstrated is the efficient internalization and degradation of cell-
surface CD4, the receptor for the HIV-1 envelope protein. The biological
purpose of this internalization has, however, remained unclear.
Results: Using human 293T cells expressing high levels of cell-surface CD4 or
CD8, we demonstrate that CD4, but not CD8, can dramatically reduce the
release of infectious virions bearing the HIV-1 envelope protein and induce a
concomitant increase in the accumulation of cell-associated HIV-1 structural
proteins. In contrast, CD4 had no effect on the release of HIV-1 bearing a
heterologous envelope protein unable to bind CD4. Nef expression totally
reversed CD4-mediated inhibition but only if the CD4 used remained
susceptible to Nef-induced internalization. 
Conclusions: These results support the hypothesis that cell-surface CD4 can
interact with the envelope protein present on budding HIV-1 virions to inhibit
their release. The internalization and degradation of cell-surface CD4 induced
by the viral Nef protein can fully reverse this inhibition and is, therefore, likely to
facilitate the spread of virus in vivo.
Background
Infection of cells by human immunodeficiency virus
type 1 (HIV-1) requires an initial interaction between the
viral envelope protein (Env) and the cell-surface CD4
glyco-protein [1–5]. Remarkably, no less than three out of
a total of nine gene products encoded by HIV-1 can
specifically inhibit the cell-surface expression of CD4 and,
hence, render cells resistant to infection (reviewed in [6]).
The first of these is Nef, a viral early gene product that
induces the internalization and degradation of cell-surface
CD4 molecules [7–11]. In contrast, the viral Env protein,
which is a late gene product, forms a complex with CD4 in
the endoplasmic reticulum (ER), resulting in the retention
of both newly synthesized CD4 and Env in the ER [12].
Finally, Vpu, another late viral gene product, binds the
intracytoplasmic domain of CD4 molecules in the ER and
then targets them for degradation by the proteasome
[13,14]. Vpu, therefore, not only prevents newly synthe-
sized CD4 from reaching the cell membrane but also sig-
nificantly increases cell-surface expression of Env. In
contrast, Nef does not affect CD4 production but induces
the rapid removal of pre-existing CD4 molecules from the
surface of the cell shortly after HIV-1 infection [7–9].
Although the interaction of Env with CD4 in the ER
could be viewed as inadvertent, and the role of Vpu as
being primarily to facilitate the efficient transport of Env
to the cell surface in CD4-expressing cells, it appears that
CD4 downregulation by Nef is designed to selectively
remove this essential HIV-1 receptor from the surface of
infected cells. Because this action renders cells refractory
to HIV-1 infection [11], Nef might be acting to prevent
the cytopathic effects induced by retroviral super-
infection. Alternatively, the removal of cell-surface CD4
might facilitate the release of progeny HIV-1 virions that
might otherwise be trapped by CD4 molecules present in
the plasma membrane of infected cells. Despite the attrac-
tiveness of this latter hypothesis, no evidence has yet
been reported to support it.
Downregulation of CD4 by Nef is believed to involve the
direct and specific interaction of Nef with, on the one
hand, a dileucine motif present in the CD4 intracyto-
plasmic domain [7,15,16] and, on the other, one or more
adaptor protein (AP) complexes [17–19]. These AP com-
plexes are then believed to target CD4 for internalization
by way of clathrin-coated pits and finally for degradation
in lysosomes. Nef also induces the internalization and
degradation of class I MHC molecules, the removal of
which might confer partial resistance to lysis of the
infected cell by HIV-1-specific cytotoxic T lymphocytes
in vivo [17,18,20]. Class I MHC internalization is also
thought to involve binding of Nef to the class I MHC
intracytoplasmic domain, albeit to a different target
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sequence from that in CD4, and to AP complexes [17,18].
In addition to CD4 and class I MHC downregulation, Nef
has also been reported to cause a modest increase in the
infectivity of HIV-1 virions produced from nef-expressing
cells [21–25]. This increased infectivity can vary from
imperceptible to more than 10-fold, depending on the
experimental system used, but is most obvious when qui-
escent T cells are infected before activation [21,22].
These latter two activities of Nef are, at least in part, func-
tionally distinct from CD4 downregulation, in that muta-
tion of a proline-rich SH3-binding motif in Nef has been
reported to inhibit both class I MHC downregulation and
Nef-enhanced virion infectivity, yet does not reduce the
efficiency of CD4 downregulation [15,17,26]. Finally, Nef
expression has also been reported to affect the activation
state of cells [27,28], although the significance of this
finding, and whether it represents yet a fourth indepen-
dent phenotype of Nef, is still unclear.
Despite the varied activities ascribed to the nef gene
product, Nef has only a modest positive effect on HIV-1
replication in culture in most experimental systems
[21,29,30]. In vivo evidence from monkeys infected with
simian immunodeficiency virus (SIV) [29], as well as from
HIV-1-infected immunodeficient mice implanted with
human tissues [31], clearly shows that Nef is important for
efficient viral replication and, hence, for pathogenesis.
Even in vivo, however, Nef is not absolutely essential. For
example, in neonatal monkeys, SIV carrying deletions in
nef can occasionally replicate to appreciable titers and cause
disease [32]. The fact that the nef gene product as a whole
is not critical for HIV-1 replication implies that the individ-
ual contributions of the three or four distinct Nef activities
to the overall rate of viral replication might well be modest.
The hypothesis that cell-surface CD4 can inhibit the
release of progeny HIV-1 virions from infected cells pre-
dicts that the level of inhibition should be proportional to
the amount of cell-surface CD4. It has, in fact, previously
been shown that cells expressing very high levels of CD4
are unable to support a spreading HIV-1 infection in
culture [33]. Conversely, the increase in the release of
progeny HIV-1 virions that results from the Nef-mediated
downregulation of cell-surface CD4, if it occurs, should
become more apparent with higher initial levels of CD4
expression. We therefore examined the effect of Nef on
the release of HIV-1 virions from 293T cells, which
express a level of CD4 ~20-fold higher than the average
level on transformed T cells. We observed that Nef could
indeed dramatically enhance the release of HIV-1 virions
from these CD4+ cells, but not from 293T cells expressing
comparable levels of CD8. This effect was abrogated
when a CD4 mutant refractory to Nef downregulation was
used, or when the HIV-1 Env protein was replaced with
an amphotropic murine retroviral Env protein. These data,
therefore, show that cell-surface CD4 can indeed inhibit
the release of progeny HIV-1 virions and they provide evi-
dence for the hypothesis that CD4 downregulation by Nef
can effectively counter this inhibition.
Results
To test the hypothesis that cell-surface CD4 can specifi-
cally inhibit the release of progeny HIV-1 virions by
forming complexes with the viral Env protein on the virion
surface, and that Nef can alleviate this inhibition by induc-
ing the internalization and degradation of cell-surface
CD4, we followed the experimental protocol diagrammed
in Figure 1. On day 1, 293T cells were transfected with an
expression vector encoding wild-type or mutant (Nef-non-
responsive) CD4, with CD4 plus Lck, with CD8, with
CD8 plus Lck or with the blank vector. At ~70 hours after
transfection, the cells were harvested and stained with an
anti-CD4 monoclonal antibody, an anti-CD8 monoclonal
antibody or, in the case of control transfected cells, mock
stained. The cells were then subjected to fluorescence-
activated cell sorting (FACS) and the most highly express-
ing ~15% cells harvested. The transfection efficiency was
~50%, in that 53 ± 4% of cells were gated as CD4+, and
49 ± 4% gated as CD8+, averaged over four experiments.
Control transfected cells were also passed through the
FACScan but were not sorted. The relative levels of
expression of CD4 on the harvested population of trans-
fected 293T cells were compared with the levels seen on
four representative human T-cell lines (SupT1, H9, CEM-
SS and HUT78) analyzed in parallel. Results showed that
the cell-surface level of CD4 on these 293T cells varied
between ~12-fold higher than the highest CD4 level seen
(on SupT1) and ~35-fold higher than the lowest level seen
(on CEM-SS; data not shown). A representative FACS
analysis comparing the level of anti-CD4 monoclonal anti-
body staining observed with mock-transfected 293T cells,
614 Current Biology, Vol 9 No 12
Figure 1
Overview of the experimental protocol used to analyze the effect of
CD4 and Nef on the efficiency of HIV-1 release from transfected 293T
cells. FACS, fluorescence-activated cell sorting; Luc, luciferase;
ELISA, enzyme-linked immunosorbent assay. See the text for a
detailed discussion.
Transfect 293T cells with CD4 or CD8 – Lck.
Harvest and stain cells for CD4 or CD8. 
Collect highly positive cells by FACS and plate.
Transfect sorted cells with 
Env– Luc+ HIV-1 provirus + Env – Nef.
Harvest supernatant media for p24 ELISA and 
infectivity assays. Harvest cells for p24 western blot.
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with 293T cells transfected with the CD4 expression
plasmid, or with the CD4+ T-cell line SupT1 is given in
Figure 2a.
After harvesting, the different pools of 293T cells were
each plated onto 35-mm dishes, at ~3 × 105 cells per plate,
and allowed to recover for ~24 hours. At this point, cells
were transfected with the pNL-Luc+E–R–HIV-1 proviral
expression plasmid [34] together with pCR3.1-based
expression plasmids encoding a CCR-5-tropic HIV-1 Env
protein, or a murine leukemia virus (MLV)-derived
amphotropic Env protein, and either wild-type or mutant
forms of HIV-1 Nef or SIVmac239 Nef (Nef-S). The Nef
expression plasmids were substituted with the blank
pCR3.1 plasmid where appropriate. The HIV-1 provirus
present in the pNL-Luc+E–R– plasmid lacks a functional
env gene and bears the luciferase indicator gene in place
of nef [34]. When pseudotyped by a functional Env
protein expressed in trans, the released NL-Luc+E–R–
virions are able to undergo one round of infection and
then express readily quantifiable levels of luciferase in
the infected cells.
At ~63 hours after the second transfection, supernatant
media were harvested and analyzed for expression of the
internal structural viral protein p24 Gag by ELISA and for
infectious virus. For this purpose, 1 ml supernatant media
was overlaid onto 293T cells that had been transfected
with plasmids expressing CD4 and the CCR-5 co-recep-
tor as previously described [35]. Luciferase levels were
quantified at 48 hours after infection and represent an
accurate measure of the level of infectious virus in the
supernatant media.
We and others have previously shown that HIV-1 Nef can
greatly reduce the level of cell-surface CD4 when these
proteins are co-expressed in transfected 293T cells
[7,11,15]. To confirm this earlier result, and to address
whether expression of HIV-1 Env, or expression of the
HIV-1 Vpu protein encoded by the NL-Luc+E–R–
provirus, would exert a significant effect on the level of
cell-surface CD4 during the course of this experimental
procedure, we performed a FACS analysis on the re-trans-
fected CD4+ 293T cells on day 7, that is one day before
virus harvest (Figure 1). The anti-CD4 monoclonal anti-
body used, termed L120, was chosen because it recog-
nizes a CD4 epitope that is not occluded by the HIV-1
Env protein [36]. As shown in Figure 2b, CD4+ cells trans-
fected with NL-Luc+E–R– and the Env expression
plasmid in fact showed only a very modest (~15%) reduc-
tion in the level of cell-surface CD4 at this time point. In
contrast, the level of CD4 on the surface of cells trans-
fected with the Nef expression plasmid was reduced by
~90%, and this reduction was not further enhanced by co-
expression of Env. Therefore, at this point in the experi-
ment, pre-existing cell-surface CD4 has been effectively
downregulated by Nef, whereas Env and Vpu, which act
only on newly synthesized CD4, have yet to exert a
marked effect.
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Figure 2
Analysis of cell-surface CD4 expression levels. (a) Relative level of
staining, by a fluorescein-conjugated Q4120 anti-CD4 monoclonal
antibody, of mock-transfected 293T cells, CD4-transfected 293T cells
(293T + CD4), and of SupT1, which is a CD4+ human T-cell line. The
sorted CD4+ 293T cells are indicated by the bar. (b) Relative cell-
surface CD4 expression levels on sorted CD4+ 293T cells which had
been subsequently mock transfected (Neg) or transfected with the
indicated expression plasmids were determined by FACS analysis at
~44 h after the second transfection (see Figure 1) using the
phycoerythrin-conjugated L120 anti-CD4 monoclonal antibody. Both
(a) and (b) show one representative experiment.
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Inhibition of virion release by cell-surface CD4 is relieved
by Nef
To examine the effect of Nef on HIV-1 virion release, we
transfected control 293T cells, or cells expressing CD4 or
CD8 in the presence or absence of the tyrosine kinase Lck,
with the NL-Luc+E–R– provirus and an HIV-1-derived env
expression plasmid in the presence or absence of an HIV-1
nef expression plasmid. CD8, which neither binds the
HIV-1 Env protein nor is affected by Nef, served as a neg-
ative control. Lck, which interacts with both CD4 and
CD8, was included to see if it would exert any effect in this
assay. Western analysis confirmed that Lck was indeed
expressed by the transfected 293T cells (data not shown).
As shown in Figure 3a, co-expression of both Env and Nef,
in the absence of any CD4, resulted in an approximatley
twofold increase in the level of supernatant p24 Gag when
compared with the level seen with NL-Luc+E–R– and Env
(Env only). In contrast, co-expression of Env with CD4, or
with CD4 plus Lck, resulted in an approximately fivefold
drop in the level of released p24 compared with the control,
Env-only cells or with cells co-transfected with CD8 ± Lck
(Figure 3a). Remarkably, the additional expression of Nef
resulted in a complete reversal of this CD4-induced inhibi-
tion and fully restored p24 Gag production to the level seen
in the absence of CD4 expression. In contrast, Nef had
little or no effect on supernatant p24 Gag levels when co-
expressed with CD8. Lck appeared to have little or no
effect on the level of HIV-1 production when expressed
with either CD4 or CD8 (Figure 3a).
Because Nef has been proposed to enhance the infectivity
of HIV-1 virions produced in its presence [21–25], includ-
ing that of virions produced from transfected 293T cells
[24], we wished to contrast the level of infectious virions
released in this experiment with the level of p24 Gag pro-
duction, which measures the total level of released infec-
tious and noninfectious virion capsids. In fact, we
observed very little difference between the p24 data, pre-
sented in Figure 3a, and the infectious virus data, pre-
sented in Figure 3b. Specifically, CD4 ± Lck was again
found to inhibit the release of infectious HIV-1 strongly,
and this inhibition was again effectively rescued by co-
expression of nef. In contrast, Nef had no significant effect
on the level of infectious virus produced from
CD8-expressing cells. It is possible to derive a coefficient
that measures the relative infectivity of the HIV-1 virions
released in the presence or absence of Nef by dividing the
relative level of infectious virus present per milliliter of
supernatant (Figure 3b) by the relative level of p24 Gag
protein per milliliter (Figure 3a). These numbers, which
are given in parentheses in Figure 3b, show that Nef had
little or no effect on HIV-1 virion infectivity. Instead, the
major effect of Nef was to rescue the release of infectious
virus from CD4-expressing cells. In subsequent experi-
ments, we have, therefore, presented only data quantify-
ing the level of release of infectious HIV-1 virions.
Effect of CD4 and Nef on cell-associated virus
The data in Figure 3 show that cell-surface CD4 inhibits
the release of HIV-1 virions from transfected 293T cells
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Figure 3
Inhibition of virion production by cell-surface CD4 is reversed by HIV-1
Nef. Control 293T cells, as well as 293T cells expressing CD4 or CD8
plus or minus Lck, were transfected with the pNL-Luc+E–R– HIV-1
proviral expression plasmid, and a plasmid expressing an R5 tropic Env
protein, in the presence or absence of an HIV-1 Nef expression
plasmid. Levels of (a) supernatant p24 Gag protein or (b) infectious
HIV-1 were analyzed ~63 h later and are given relative to the level
observed in the CD4–/CD8– 293T cell culture transfected with
pNL-Luc+E–R– plus the Env expression plasmid (Env only), which was
arbitrarily set at 100%. The data represent the average of three
experiments plus or minus the standard deviation. (a) Released p24
levels were determined by ELISA. For the ‘Env only’ sample, these
averaged ~25 ng/ml over three experiments. (b) Infectious virus levels
were determined by overlaying 1 ml filtered supernatant media onto
293T cells that express CD4 and CCR-5. After incubation for 2 days,
the cells were harvested and lysed and the level of luciferase
expression determined. Because the luciferase gene is expressed as
part of the defective Luc+E–R– HIV-1 genome, this yields an accurate
measure of the level of infectious virus [34,35]. Numbers in brackets at
the end of each bar give the relative infectivity of the virions present in
each sample and were derived by dividing the level of infectious virus
(b) by the level of released virus (a).
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and that this inhibition is reversed by expression of HIV-1
Nef. These data are consistent with the hypothesis that
CD4 and Nef affect only virus release, and not virus pro-
duction, but it is also possible that CD4 and Nef have no
direct effect on the efficiency of virion release but are
instead simply acting to respectively inhibit or boost the
synthesis of viral proteins. If the latter case is true, then
CD4 expression should also reduce the level of cell-associ-
ated Gag protein whereas Nef should enhance it. In con-
trast, if the level of virus production is constant, and CD4
and Nef are acting at the level of virus release, then cell-
associated p24 Gag should increase in the presence of
CD4 and decrease in the presence of Nef. As shown in the
western analysis in Figure 4, expression of CD4 in fact
increases the level of cell-associated p24 Gag in the trans-
fected 293T cells by twofold to threefold (compare lanes 2
and 3), whereas the co-expression of CD4 with Nef
reduces cell-associated p24 levels by approximately
sixfold, to a level slightly below that seen in the control
CD4– lane. These data therefore strongly support the
hypothesis that Nef is indeed acting to reverse the reten-
tion of budding virions caused by cell-surface CD4.
We asked next whether this activity was unique to HIV-1
Nef or whether other Nef proteins would also be active.
As shown in Figure 5, the Nef protein encoded by
SIVmac239 Nef, which can also downregulate the cell-
surface expression of human CD4 when expressed in
293T cells [15], could also reverse the inhibition in HIV-1
virus release induced by CD4 expression. Interestingly,
SIV Nef did not, however, give rise to the modest (around
twofold) CD4-independent increase in infectious HIV-1
virus release seen with HIV-1 Nef (Figure 3).
Downregulation of cell-surface CD4 is critical for the effect
of Nef on virion release 
If Nef is indeed acting to prevent an inhibitory effect of
cell-surface CD4 on virion release, then the ability of Nef
to induce CD4 internalization should be essential for this
activity. To test this hypothesis, we expressed a previously
described mutant form of CD4 (LS414/415AA) [15] which
is totally refractory to Nef-induced internalization but is
expressed at similar levels to wild-type CD4 on the surface
of transfected cells. This CD4 mutant (mCD4) was compa-
rable with wild-type in its ability to inhibit the production
of HIV-1 from 293T cells (Figure 5). In contrast to wild-
type CD4, however, this inhibition was not relieved by
expression of Nef. Therefore, the internalization and
degradation of cell-surface CD4 is key to the positive
effect of Nef on virus production observed in these studies.
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Figure 4
Western analysis for cell-associated p24 Gag protein. Transfected 293T
cells, remaining at the end of an experiment included in Figure 2, were
harvested after removal of the virus-containing supernatant and were
then analyzed for levels of cell-associated p24 Gag (shown by the arrow)
by western analysis using a rabbit polyclonal anti-HIV-1 p24 antiserum
[45] and enhanced chemiluminescence. Lane 1, mock-transfected 293T
cells; lane 2, NL-Luc+E–R– + Env; lane 3, NL-Luc+E–R– + Env + CD4 +
Lck; lane 4, NL-Luc+E–R– + Env + CD4 + Lck + Nef. The relative
mobility of molecular weight markers run in parallel is given at left.
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Figure 5
Specificity of the CD4/Nef effect on HIV-1 virion release. This
experiment was performed as described in Figures 1 and 2 and
examines the effect of substituting SIVmac239 Nef (Nef-S) in place of
HIV-1 Nef, of substituting a CD4 mutant (mCD4) that is refractory to
downregulation by HIV-1 Nef in place of wild-type human CD4, or of
substituting an MLV amphotropic Env (Ampho) in place of HIV-1 Env,
on the inhibition of HIV-1 virion release by CD4 and/or the rescue of
this inhibition by Nef. Data represent the average of three experiments
and were derived as described in Figure 3.
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CD4 inhibition of HIV-1 virion release requires the HIV-1
Env protein 
The model under analysis predicts that the retention of
HIV-1 virions by CD4 is due to an interaction, at the cell
surface, between CD4 and the HIV-1 Env protein present
on budding virions. Therefore, if the Env protein used to
pseudotype the pNL-Luc+E–R– provirus is not able to
interact with CD4, no inhibition of virion release, and
hence no rescue by HIV-1 Nef, should be observed. To
test this hypothesis, we pseudotyped this HIV-1 provirus
with an MLV amphotropic Env protein that is known to
efficiently pseudotype HIV-1 virions [24]. As shown in
Figure 5, virions produced in the presence of amphotropic
Env were comparable in infectivity to virions bearing the
HIV-1 Env protein. CD4 co-expression could not exert
any inhibitory effect on the release of these infectious,
amphotropic Env+ HIV-1 virions, and the additional
expression of Nef therefore had little positive effect on
virus production. No luciferase activity was detected when
the supernatant media from 293T cells transfected with
pNL-Luc+E–R– in the absence of an Env expression
plasmid were analyzed (data not shown).
The Nef SH3 motif is not required for enhanced virion
release from CD4+ cells 
Although the domain organization of Nef remains incom-
pletely defined, there has been considerable interest in a
proline motif, located between Nef residues 69 and 78,
that seems to function as an Src homology region 3
(SH3)-binding motif [17,26,37]. Interestingly, mutagene-
sis of this motif, and particularly of prolines at positions
72 and 75, blocks the enhancing effect of Nef on virion
infectivity, the ability of Nef to downregulate class I
MHC and the ability of Nef to interact with certain tyro-
sine kinases in vitro [17,26]. In contrast, the integrity of
this motif is not required for efficient downregulation of
cell-surface CD4 [26,38].
To test the role of this SH3 motif in the observed
enhancement by Nef of HIV-1 release from CD4+ cells,
we compared the biological activity of wild-type Nef with
two previously described Nef mutants mutated at either
proline 72 (P72L) or at proline 75 (VP74/75LA) [38]. Both
mutants are effectively expressed and retain the ability to
downregulate cell-surface CD4. As shown in Figure 6,
both these mutants also retain the ability to rescue the
inhibition of HIV-1 release induced by CD4 either in the
presence or absence of Lck. Comparison of the data in
Figure 6 with those in Figure 3b reveals that, although
both these mutants can restore virion release to the level
seen in the absence of either CD4 or Nef, they do not
share the ability of wild-type Nef to enhance infectious
virus production by an additional twofold. The signifi-
cance of this result is discussed below.
Discussion
Of the biological activities that have been assigned to the
HIV-1 Nef protein — downregulation of cell-surface CD4
and class I MHC, enhancement of virion infectivity, and
possibly also increased activation of expressing cells —
downregulation of the CD4 receptor was the first to be
reported [10,39] and has been extensively confirmed
[7–9,11,15,19,26,38]. The purpose of this downregulation
has remained unclear, however. The specific removal by
viruses of their cognate receptor from the surface of
infected cells is not, however, uncommon. One of the best
studied examples is influenza virus. The viral enzyme
neuraminidase (NA) specifically destroys the cell-surface
sialic acid receptor for influenza virus [40,41]. In the
absence of NA, infection proceeds normally, but progeny
influenza virions are unable to leave the infected cell and
instead aggregate on the cell surface.
Whereas NA is critical for influenza virus replication both
in culture and in vivo, Nef is largely dispensable for HIV-1
replication in culture [21,29,30] and, although important
for efficient HIV-1 replication in vivo [29,31], it is never-
theless not essential [32]. Thus, the combined phenotype
of all the activities assigned to Nef is relatively modest and
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Figure 6
Effect of mutation of the Nef SH3-binding motif on the rescue of virion
release from CD4+ cells. This experiment was performed as
described in Figure 2 except that two previously described [38] HIV-1
Nef mutants lacking a functional SH3-binding motif were substituted
in place of wild-type Nef. M72 bears a leucine in place of proline 72
(P72L) whereas M75 encodes leucine and alanine in place of valine
and proline at residues 74 and 75 (VP74/75LA). These data
represent the average of three experiments and were derived as
described in Figure 3.
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the contribution of CD4 downregulation alone to efficient
virus replication would be expected to be more modest
still. Thus, if Nef-mediated downregulation of CD4 does
indeed enhance the release of progeny HIV-1 virions from
infected cells, then this enhancement must clearly be
minor, at least in culture. Nevertheless, as pointed out by
Coffin [42], even a very small advantage on a per genera-
tion basis can exert a dramatic effect on the relative fitness
of a virus that replicates as rapidly as HIV-1. Unfortu-
nately, if the increase in the replication potential of HIV-1
that arises specifically from CD4 downregulation is indeed
small, say less than 10% per replication cycle, then it would
be difficult to measure with available techniques. The fact
that mutations that are clearly specific for particular Nef
activities are not yet available has also made it difficult to
dissect the contribution of each distinct Nef activity to the
composite Nef phenotype.
Downregulation of CD4 by Nef would therefore seem
unlikely to have a marked phenotype on a single replica-
tion cycle basis in cultured cells expressing physiological
levels of cell-surface CD4. We circumvented this problem
by asking whether this phenotype would become more
obvious in cells with higher levels of cell-surface CD4.
Specifically, we asked whether high levels of CD4 would
block virion release and, more important, whether expres-
sion of Nef would reverse this block. This approach is
valid if the likelihood that a progeny HIV-1 virion would
encounter a cell-surface CD4 molecule during, or immedi-
ately after, budding is proportional to the level of expres-
sion of CD4 on the surface. If this is true, then increasing
the level of CD4 expression should make evident a
phenotype that, although real, is normally difficult to
detect. We therefore carried out these experiments using
FACS-sorted 293T cells that express high levels of CD4
or CD8, either in the presence or absence of Lck. These
sorted cells were then transfected with the defective
pNL-Luc+E–R– provirus [34], together with an Env
expression plasmid, and the effect of CD4 and Nef on the
efficiency of virus release was determined.
As shown in Figure 3, CD4, but not CD8, inhibited HIV-1
virion release by around fivefold and this inhibition was
more than rescued by co-expression of HIV-1 Nef. Similar
results were obtained whether total released p24 Gag
protein (Figure 3a) or total released infectious virus
(Figure 3b) was determined. As predicted by the hypothe-
sis that CD4 causes retention of progeny HIV-1 virions
whereas Nef facilitates virion budding, CD4 induced an
increase in cell-associated p24 Gag in these transfected
293T cells that was reversed by HIV-1 Nef (Figure 4).
Further analysis revealed that SIV Nef could also block
CD4-induced inhibition of HIV-1 virion release (Figure 5).
A mutant CD4 lacking a functional dileucine motif that is
required for Nef downregulation caused an inhibition in
HIV-1 virion release that proved refractory to rescue by
Nef (Figure 5). Substitution of the HIV-1 Env protein with
an envelope protein derived from an amphotropic MLV,
which does not recognize CD4, blocked the inhibition of
HIV-1 release caused by CD4 overexpression; the further
expression of Nef therefore gave only a modest positive
effect (Figure 5). Together, these data strongly support the
hypothesis that cell-surface CD4 can block the release of
progeny HIV-1 virions by interacting with HIV-1 Env
protein assembled onto budding virus particles, and that
the specific downregulation and degradation of cell-surface
CD4 caused by Nef can effectively alleviate this retention.
We therefore propose that the Nef-mediated downregula-
tion of CD4 of HIV’s host cells in vivo contributes to the
effective spread of the virus in the infected host by facili-
tating progeny virion release.
When we started these experiments, we expected that the
reported enhancing effect of Nef on the relative infectiv-
ity of progeny HIV-1 virions [21–25] would complicate the
interpretation of our results. It has been reported that co-
expression of Nef can enhance the infectivity of HIV-1
virions produced in 293T cells by 4–40-fold [24]. In con-
trast, we consistently failed to see any significant effect of
Nef on specific virion infectivity (Figure 3b, and data not
shown). Our experiments were performed using a CCR-5-
tropic envelope, rather than the CXCR-4-tropic envelope
used previously [24], and we measured relative infectivity
on CD4+ CCR-5+ 293T cells, whereas earlier work used
CD4+ HeLa cells [24]. Although these experimental dif-
ferences might largely explain this discrepancy, we note
that a 10-fold infectivity advantage for Nef-expressing
HIV-1 virions on a per generation basis should produce
differences of several orders of magnitude in the level of
virus replication, relative to Nef– HIV-1, when measured
over many generations. In fact, such large differences
were not observed when the level of replication of Nef–
versus Nef+ HIV-1 was compared in either CD4+ T-cell
lines or activated primary T cells [21,30] or when wild-
type SIVmac239, which carries a biologically active nef gene,
was compared with a Nef– form in primary rhesus monkey
T cells or macrophages [29]. It is therefore possible that
the large effect of Nef on virion infectivity seen upon
infection of CD4+ HeLa cells is not representative of
CD4+ cells in general. This question clearly merits exami-
nation in more detail.
Although we did not detect any significant effect of Nef
on relative virion infectivity, we did note a small, around
twofold, effect of Nef on the level of total or infectious
progeny virion release even in the absence of CD4 or
HIV-1 Env (Figures 3,5). This effect, although quite
modest, did appear specific in that it was lost upon muta-
tion of the HIV-1 Nef SH3-binding motif (Figure 6) and
was not detected when SIV Nef was used (Figure 5). The
level of cell-associated p24 present in Nef-expressing cells,
even in the presence of CD4, was actually observed in
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some experiments to be below the level seen in cells
expressing neither CD4 or Nef (Figure 4, compare lanes 2
and 4). This might suggest that Nef can modestly facilitate
HIV-1 virion release even in the absence of cell-surface
CD4, a result that is intriguing in light of recent data sug-
gesting that Nef could exert exactly such an effect [43].
Nevertheless, it is apparent from these data that the major
positive effect of Nef on the efficiency of progeny HIV-1
virion release is likely to be from CD4-positive, and partic-
ularly from strongly CD4-positive, infected cells.
Conclusions
Using a transfection assay in HIV-1-permissive human
293T cells, we show that high-level expression of cell-
surface CD4, but not of CD8, results in inhibition of the
release of progeny HIV-1 virions. An equivalent degree of
inhibition was observed regardless of whether total
released virions or only released infectious virus was mea-
sured. Co-expression of either HIV-1 or SIV Nef in the
virus-producing cells entirely reversed the inhibition
caused by wild-type CD4, but did not affect the degree of
inhibition caused by a CD4 mutant that is refractory to
internalization in the presence of Nef. Together, these
data demonstrate that cell-surface CD4 can inhibit the
release of progeny virions from infected cells and suggest
that the internalization and degradation of cell-surface
CD4 induced by Nef is designed to prevent this effect
and thus to increase virus spread in vivo.
Materials and methods
Construction of molecular clones
The LMN-1 expression plasmid is an MLV-based retroviral vector,
derived from the previously described pBMN-Z [44], that contains an
internal cytomegalovirus immediate early (CMV-IE) promoter element.
Wild-type human CD4 and CD8 cDNAs, as well as the previously
described LS414/415AA CD4 mutant [15], were amplified by poly-
merase chain reaction (PCR), inserted into pLMN-1 and expressed
under the control of the CMV-IE promoter element. The human LCK
gene was also PCR-amplified and expressed under the control of the
MLV 5′ long terminal repeat promoter present in the same plasmid. The
LMN-1 plasmid does not contain an SV40 origin of replication.
An expression plasmid, based on pCR3.1 (Invitrogen), that expresses
the CCR-5-tropic HIV-1 strain ADA env gene has been described [35].
An equivalent plasmid expressing an MLV amphotropic env gene [24]
was constructed by PCR amplification of this viral gene followed by
insertion into pCR3.1. The pCR3.1 expression plasmids encoding the
wild-type HIV-1 strain NL4-3 nef gene, the previously described HIV-1
nef mutants P72L and VP74/75LA [37] or the SIVmac239 nef gene [29]
were constructed similarly.
Transfection assays
Human 293T cells were maintained as described [35] and were plated
at 5 × 105 cells per 35-mm well in six-well plates. The next day, the
cells were transfected with 2 µg of an expression plasmid encoding
CD4 or CD8 plus or minus Lck, or with the blank LMN-1 plasmid, using
lipofectamine. At ~70 h after transfection, the cells were harvested and
stained with an anti-CD4 monoclonal antibody (Q4120, Sigma), an
anti-CD8 monoclonal antibody (UCHT-4, Sigma) or were mock stained
[15]. The cells were then sorted by FACS, using a FACScan machine
(Becton-Dickinson), and the most intensely fluorescent ~15% of the
CD4- and CD8-transfected 293T cells were harvested and replated at
3 × 105 cells per 35-mm dish. In parallel, control-transfected 293T cells
were also passed through the FACScan, but not sorted, and also
plated at 3 × 105 cells per 35-mm dish.
After overnight recovery, the cells were again transfected, using lipo-
fectamine, with 500 ng pNL-Luc+E–R– [34], 500 ng env expression
plasmid, 500 ng nef expression plasmid and 500 ng parental pCR3.1
plasmid. Where appropriate, pCR3.1 DNA was substituted for the nef
expression plasmid. In some cases, cells were harvested at ~44 h after
this second transfection and then analyzed for cell-surface CD4
expression by FACS using the L120 monoclonal antibody [36] which
does not block HIV-1 Env binding to CD4 (Becton-Dickinson). Alterna-
tively, at ~63 h after this second transfection, supernatant media were
harvested and an aliquot analyzed for p24 Gag levels using commercial
ELISA (NEN Life Sciences). The remaining supernatant media were
passed through an 0.2 µm filter and 1 ml used to infect a target cell
culture. The transfected cells remaining in the plate were also har-
vested and analyzed by western blotting.
Virus infection assays
These were performed as described [35]. Briefly, 293T cells (35-mm
cultures) were transfected with previously described [35] expression
plasmids encoding human CD4 and CCR-5. Two days after transfec-
tion, the supernatant media were removed and replaced with 1 ml fresh
medium and 1 ml virus-containing medium. The infected cells were
lysed two days post-infection and then assayed for luciferase activity as
previously described [35].
Western blot analysis
The transfected cells remaining at the end of the above transfection pro-
cedure were harvested, lysed [15] and equal aliquots loaded onto a
12% polyacrylamide/SDS gel. The resolved proteins were transferred
onto a nitrocellulose membrane (Amersham) and incubated with a
1:1000 dilution of a polyclonal rabbit anti-HIV-1 p24 Gag antiserum [45]
in PBS containing 0.1% Tween 20 and 1% nonfat dry milk. After exten-
sive washing of the membrane, bound rabbit antibodies were detected
using a 1:1000 dilution of a horseradish peroxidase-conjugated goat
anti-rabbit antiserum and enhanced chemiluminescence (Amersham). 
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